

RESEARCH LETTER

Open Access



The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis

Muhammad Aziz^{1*}, Rawish Fatima¹, Wade Lee-Smith² and Ragheb Assaly³

Keywords: Hypoalbuminemia, COVID-19, SARS-CoV-2, Severe disease

The coronavirus disease 2019 (COVID-19) pandemic necessitates identifying laboratory markers to assist the clinicians in early recognition of severe disease [1]. Given the unclear association of hypoalbuminemia and severe COVID-19, we conducted a systematic review and meta-analysis to answer this.

An extensive literature search of PubMed/MEDLINE, Embase, Cochrane, and Web of Science was conducted through April 3, 2020, using search strategy created by an experienced librarian (W.L.S). Two independent reviewers (M.A. and R.F.) performed screening and data extraction of articles. Articles were selected if they reported data on COVID-19 patients with respect to hypoalbuminemia. Discrepancy in screening/data collection was resolved through mutual discussion. Random-effects meta-analysis was conducted, and odds ratio (OR) and mean difference (MD) for proportional and continuous variables were computed, respectively. For each outcome, forest plot, 95% confidence interval (CI), *p* value (< 0.05 considered statistically significant), and *I*² statistic (> 50% considered as substantial heterogeneity) was generated using Open Meta Analyst (CEBM, Oxford, UK).

Severe COVID-19 was defined as respiratory distress (with either rate \geq 30/min, oxygen saturation \leq 93% at rest, and/or PaO₂/FiO₂ \leq 300 mmHg), ICU admission, and/or death [1]. Hypoalbuminemia was reported based on reference laboratory parameters for each study.

A total of 11 studies (with 910 patients, mean age 47.6 ± 8.2 years and 47.0% females) were included (Table 1). The weighted mean serum albumin on admission was 3.50 g/dL (CI 3.26–3.74 g/dL) and 4.05 g/dL (CI 3.82–4.27 g/dL) in severe and non-severe COVID-19 group, respectively. This was statistically significant (MD: -0.56 g/dL, CI -0.69 to -0.42 g/dL, *p* < 0.001, *I*² = 91.2%) (Fig. 1a). Leave-one-out meta-analysis was consistent with point estimate (MD) ranging from -0.61 to -0.51 g/dL (Fig. 1b). The results were consistent on subgroup analysis of 8 studies that defined severe COVID-19 based on respiratory distress definition (MD -0.58 g/dL, 95% CI -0.78 to -0.37 g/dL, *p* < 0.001, *I*² = 87.9%). Four studies assessed the hypoalbuminemia status and severe COVID-19 and increased risk was demonstrated (OR 12.6, 95% CI 7.5–21.1, *p* < 0.001, *I*² = 0%) (Fig. 1c).

Hypoalbuminemia status has been associated with critically ill patients and mortality across numerous clinical settings [13]. The pathophysiology behind hypoalbuminemia in disease state (such as pancreatitis, infection, trauma, burn, and organ dysfunction) is thought to be secondary to increased capillary permeability, decreased protein synthesis, decreased half-life of serum albumin, decreased serum albumin total mass, increased volume of distribution, and increase expression of vascular endothelial growth factor [14]. The hallmark of severe COVID-19 includes the cytokine storm and an interplay of some of the aforementioned mechanisms [1].

Our study had some limitations. There was lack of reporting on temporal association of hypoalbuminemia

* Correspondence: marajani@hotmail.com

¹Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, USA

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Study characteristic and demographics of included patients (*n* no. of patients, *NR* not reported, *SD* standard deviation)

Study, year	Country	Language	Hospital	Study period	Total patients	Mean/ median age	Female gender, <i>n</i> (%)	Severe patients, <i>n</i> (%)	Serum albumin level, mean (SD) g/dL	
									Severe	Non-severe
Huang, 2020 [2]	China	English	Jinyintan Hospital	Dec 16 to Jan 2	41	49	11 (26.8%)	13 (31.7%)	2.83 (0.24)	3.4 (0.27)
Chen (1), 2020 [3]	China	English	Tongji Hospital	Jan 13 to Feb 28	274	NR	NR	113 (41.2%)	3.03 (0.06)	3.65 (0.26)
Liu (1), 2020 [4]	China	English	Shenzhen Third People's Hospital	Jan 11 to Jan 21	12	58.9	4 (33.3%)	6 (50.0%)	3.77 (0.25)	4.43 (0.34)
Chen (2), 2020 [5]	China	English	Tongji Hospital	Dec to Jan 27	21	56	4 (19.0%)	11 (52.4%)	3.02 (0.24)	3.73 (0.22)
Mo, 2020 [6]	China	English	Zhongnan Hospital	Jan 1 to Feb 5	155	54	69 (44.5%)	92 (59.4%)	3.6 (0.31)	3.9 (0.27)
Wan, 2020 [7]	China	English	Chongqing University Three Gorges Hospital	Jan 23 to Feb 8	135	47	63 (46.7%)	40 (29.6%)	3.59 (0.26)	4.52 (0.27)
Liu (2), 2020 [8]	China	Chinese	Multicenter	Jan 23 to Feb 8	32	38.5	12 (37.5%)	4 (12.5%)	3.55 (0.44)	4.05 (0.34)
Liu (3), 2020 [9]	China	Chinese	Jiangnan University Affiliated Hospital	Jan 10 to Jan 31	30	35	20 (66.7%)	4 (13.3%)	3.5 (0.21)	4.2 (0.28)
Liu (4), 2020 [10]	China	English	Multicenter	Dec 30 to Jan 15	78	38	39 (50.0%)	11 (14.1%)	3.66 (0.43)	4.13 (0.33)
Zhang, 2020 [11]	China	English	Zhongnan Hospital	Jan 18 to Feb 22	115	49.52	66 (57.4%)	31 (30.0%)	3.44 (0.31)	4.04 (0.28)
Zhou, 2020 [12]	China	English	Ninth Hospital of Nanchang	Jan 28 to Feb 6	17	41.7	11 (64.7%)	5 (29.4%)	4.6 (0.28)	4.49 (0.27)

*Respiratory distress (rate ≥ 30 /min, oxygen saturation $\leq 93\%$ at rest and/or PaO₂/FIO₂ ≤ 300 mmHg), ICU admission and/or death




Fig. 1 Forest plot demonstrating **a** meta-analysis comparing mean serum albumin, **b** leave-one-out meta-analysis comparing mean serum albumin, and **c** meta-analysis comparing hypoalbuminemia status for patients in severe vs non-severe group (C.I. confidence interval)

and severe COVID-19. The serum albumin level was noted on admission; however, it is difficult to make conclusive evidence whether severe COVID-19 caused hypoalbuminemia or vice versa. We were also not able to address if hypoalbuminemia should be corrected or not in the current study and needs further evaluation in future studies. The strength of our study is the reporting of large cohort of patients with consistent results across subgroup and sensitivity analysis.

We demonstrate the association of hypoalbuminemia and severe COVID-19. A low albumin level can potentially lead to early recognition of severe disease and assist clinicians in making informed decision for their patients.

Abbreviations

CI: Confidence interval; COVID-19: Coronavirus disease 2019; ICU: Intensive care unit; MD: Mean difference; *n*: No. of patients; OR: odds ratio; SD: standard deviation

Acknowledgements

None

Authors' contributions

Muhammad Aziz: planning and conducting the study, collecting, interpreting data, statistical analysis, drafting the manuscript. Rawish Fatima: collecting data, drafting the manuscript. Wade lee-smith: created the search strategy and critical revision of manuscript. Ragheb Assaly: study design and conception, critical revision of the manuscript. The authors read and approved the final manuscript

Funding

No funding received for preparing this manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not obtained as this is a systematic review and meta-analysis of published studies.

Consent for publication

Consent from patients not obtained due to reason above. All authors approved for the submission of the manuscript.

Competing interests

The authors declare no competing/conflict of interest.

Author details

¹Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, USA. ²University of Toledo Libraries, University of Toledo Medical Center, Toledo, OH, USA. ³Division of Pulmonary and Critical Care Medicine, University of Toledo Medical Center, Toledo, OH, USA.

Received: 4 May 2020 Accepted: 14 May 2020

Published online: 26 May 2020

References

1. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. *J Med Virol*. 2020. <https://doi.org/10.1002/jmv.25948>.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
3. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020;368:m1091. <https://doi.org/10.1136/bmj.m1091>.
4. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci*. 2020;63:364–74. <https://doi.org/10.1007/s11427-020-1643-8>.
5. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest*. 2020;130:2620–9. <https://doi.org/10.1172/JCI137244>.
6. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis*. 2020;ciaa270. <https://doi.org/10.1093/cid/ciaa270>.
7. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. *J Med Virol*. 2020;10.1002/jmv.25783. .
8. Liu C, Jiang ZC, Shao CX, et al. *Zhonghua Gan Zang Bing Za Zhi*. 2020;28:107–11. <https://doi.org/10.3760/cma.j.issn.1007-3418.2020.02.003>.
9. Liu M, He P, Liu HG, et al. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020;43:E016. <https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0016>.
10. Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J (Engl)*. 2020;133:1032–8. <https://doi.org/10.1097/CM9.0000000000000775>.
11. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. *Liver Int*. 2020;10.1111/liv.14455. <https://doi.org/10.1111/liv.14455>.
12. Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. *Ann Palliat Med*. 2020;9:428–36. <https://doi.org/10.21037/apm.2020.03.26>.
13. Akirov A, Masri-Iraqi H, Atamna A, Shimon I. Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients. *Am J Med*. 2017;130:1465.e11–65.e19. <https://doi.org/10.1016/j.amjmed.2017.07.020>.
14. Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and Clinical Significance. *JPEN J Parenter Enteral Nutr*. 2019;43:181–93. <https://doi.org/10.1002/jpen.1451>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

